Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY3410738 + esomeprazole
- Development stage
- Phase 1
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LY3410738 + esomeprazole is a combination therapy consisting of LY3410738, a potent and selective cholecystokinin-2 (CCK2) receptor antagonist (also known as the gastrin receptor), and esomeprazole, a proton pump inhibitor (PPI). The combination was developed by Eli Lilly to address limitations of PPI monotherapy in patients with acid-related disorders, such as gastroesophageal reflux disease (GERD). By blocking the CCK2 receptor, LY3410738 aims to inhibit the gastrin-mediated stimulation of gastric acid secretion and potentially mitigate the hypergastrinemia often observed during chronic PPI use. Clinical development focused on evaluating the synergistic effect of dual acid suppression mechanisms, particularly in patients who do not achieve adequate symptom relief with PPIs alone.
- Other names
- LY3410738 and esomeprazoleLY-3410738 and esomeprazoleLY 3410738 and esomeprazole
02
Targets
IDH1 (Isocitrate dehydrogenase [NADP] cytoplasmic)IDH2 (Isocitrate dehydrogenase [NADP], mitochondrial (mutant))CCK2R (Cholecystokinin 2 Receptor)ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on LY3410738 + esomeprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LY3410738 + esomeprazole.